GlobeNewsWire
23 Jun 2026, 12:50 UTC · 12w ago
Verdict
Headline takes no side. We score ENTX +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 93% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA provided positive feedback and accepted the Phase 3 registrational protocol for Entera Bio's oral osteoporosis tablet, EB613.
More positive than 98% of claims this week
Entera Bio expects to initiate the Phase 3 study in late 2026, with topline results anticipated in the second half of 2028.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 62% of claims this week
Recent data from ENDO 2026 shows EB613's single-tablet version has a pharmacokinetic profile comparable to the injectable Forteo.
So whatClinical proof of equivalence to an established blockbuster (Forteo) increases the probability of Phase 3 success.
More positive than 62% of claims this week
The company is leveraging its N-Tab platform to develop additional oral peptide candidates, including EB612 for hypoparathyroidism and EB618 for obesity.
So whatTransforms the company from a single-asset risk to a platform play, increasing its overall valuation and attractiveness for partnerships.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 93% of ticker scores this week
The company received positive FDA feedback on its Phase 3 protocol for EB613, establishing a clear regulatory path for a potential first-of-its-kind oral osteoporosis treatment.
More positive than 47% of ticker scores this week
Mentioned as a collaborator on multiple promising oral peptide programs for hypoparathyroidism and obesity.
More positive than 41% of ticker scores this week
Mentioned as a successful example of the commercial logic for oral peptide medicines.
Near neutral — 90% of ticker scores this week are stronger
Mentioned as the manufacturer of Forteo to provide historical context for the active hormone used in Entera Bio's drug.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3d ago
More positive than 17% of relationship scores this week
[mutual] Entera Bio's EB613 is an oral formulation of the same hormone used in Eli Lilly's Forteo.
+100.0%
Price agrees with the score
$2.96 vs $1.48 close before publication (Jun 22) · not market-adjusted
ENTX chart →
